FLAVORED COLESTID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLAVORED COLESTID (FLAVORED COLESTID).
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
| Metabolism | Colestipol is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces. |
| Excretion | Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination. |
| Half-life | Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined. |
| Protein binding | Does not bind to plasma proteins as it is not absorbed. |
| Volume of Distribution | Not applicable; minimal systemic absorption (Vd essentially 0). |
| Bioavailability | Oral bioavailability is <0.05% via absorption; acts locally in GI tract. |
| Onset of Action | LDL reduction begins within 7-10 days after oral administration; maximal effect in 4-6 weeks. |
| Duration of Action | LDL reduction persists for 2-3 weeks after cessation; resin binds bile acids without systemic accumulation. |
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
| Dosage form | GRANULE |
| Renal impairment | No specific recommendations; use caution in severe renal impairment due to potential accumulation of inactive ingredients. GFR <30 mL/min: consider alternative agents or reduced dose under clinical monitoring. |
| Liver impairment | No specific guidelines for Child-Pugh scores; no expected alterations in pharmacokinetics as drug is not systemically absorbed. Use with caution in severe hepatic impairment due to potential electrolyte disturbances. |
| Pediatric use | Not established for children under 18 years; safety and efficacy not determined. In adolescents (≥18 years) use adult dosing titrated to effect with close monitoring. |
| Geriatric use | Start at low end of dosing range (5 grams once daily); titrate slowly. Monitor for constipation, electrolyte imbalances, and drug interactions. No specific age-based dose adjustments recommended. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLAVORED COLESTID (FLAVORED COLESTID).
| Breastfeeding | Colestid is not absorbed systemically, so it is unlikely to be excreted into breast milk. No data on M/P ratio. It is considered compatible with breastfeeding, but caution is advised due to potential interference with maternal absorption of fat-soluble vitamins, which could affect milk composition. Monitor infant for signs of vitamin deficiency. |
| Teratogenic Risk | Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, use during pregnancy may impair absorption of fat-soluble vitamins (A, D, E, K), potentially affecting fetal development. Trimester-specific risks: First trimester: theoretical risk of vitamin deficiency. Second and third trimesters: risk of vitamin K deficiency leading to neonatal hemorrhage. Overall, the drug is considered low risk due to lack of systemic absorption. |
■ FDA Black Box Warning
Not applicable (no FDA black box warning).
| Serious Effects |
Complete biliary obstruction (contraindicated because ineffective). Hypersensitivity to colestipol or any component of the formulation.
| Precautions | Can cause hypertriglyceridemia; caution in patients with pre-existing hypertriglyceridemia. Risk of fat-soluble vitamin deficiency (A, D, E, K) with long-term use. May interfere with absorption of other medications; administer other drugs at least 1 hour before or 4 hours after colestipol. Constipation may worsen hemorrhoids. Use caution in patients with gastrointestinal motility disorders or history of bowel obstruction. |
Loading safety data…
| Fetal Monitoring | Monitor maternal levels of fat-soluble vitamins (A, D, E, K) periodically, especially during prolonged use. Assess prothrombin time (PT) and international normalized ratio (INR) to monitor for vitamin K deficiency. In the fetus, consider ultrasound to assess growth and development if vitamin deficiency is suspected. Monitor neonate for signs of bleeding (vitamin K deficiency) if taken near term. |
| Fertility Effects | Colestipol may interfere with absorption of fat-soluble vitamins and nutrients critical for reproductive health, but no direct effects on fertility have been reported. In animal studies, no adverse effects on fertility were observed. However, potential vitamin deficiencies could indirectly affect fertility. |